Switch to:
Also traded in: Argentina, Belgium, Brazil, Chile, Germany, Mexico, Sweden, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.33
PFE's Cash-to-Debt is ranked lower than
75% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.09 vs. PFE: 0.33 )
Ranked among companies with meaningful Cash-to-Debt only.
PFE' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.14  Med: 0.78 Max: N/A
Current: 0.33
Equity-to-Asset 0.35
PFE's Equity-to-Asset is ranked lower than
84% of the 734 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. PFE: 0.35 )
Ranked among companies with meaningful Equity-to-Asset only.
PFE' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.35  Med: 0.47 Max: 0.66
Current: 0.35
0.35
0.66
Interest Coverage 11.61
PFE's Interest Coverage is ranked lower than
71% of the 635 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 105.95 vs. PFE: 11.61 )
Ranked among companies with meaningful Interest Coverage only.
PFE' s Interest Coverage Range Over the Past 10 Years
Min: 5.27  Med: 10.39 Max: 18.94
Current: 11.61
5.27
18.94
Piotroski F-Score: 6
Altman Z-Score: 2.26
Beneish M-Score: -2.58
WACC vs ROIC
7.42%
13.73%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 26.25
PFE's Operating Margin % is ranked higher than
88% of the 744 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.42 vs. PFE: 26.25 )
Ranked among companies with meaningful Operating Margin % only.
PFE' s Operating Margin % Range Over the Past 10 Years
Min: 14.53  Med: 23.82 Max: 29.44
Current: 26.25
14.53
29.44
Net Margin % 13.92
PFE's Net Margin % is ranked higher than
76% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.16 vs. PFE: 13.92 )
Ranked among companies with meaningful Net Margin % only.
PFE' s Net Margin % Range Over the Past 10 Years
Min: 12.67  Med: 16.8 Max: 42.65
Current: 13.92
12.67
42.65
ROE % 11.92
PFE's ROE % is ranked higher than
65% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.86 vs. PFE: 11.92 )
Ranked among companies with meaningful ROE % only.
PFE' s ROE % Range Over the Past 10 Years
Min: 9.29  Med: 11.86 Max: 27.93
Current: 11.92
9.29
27.93
ROA % 4.29
PFE's ROA % is ranked higher than
54% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.49 vs. PFE: 4.29 )
Ranked among companies with meaningful ROA % only.
PFE' s ROA % Range Over the Past 10 Years
Min: 4.05  Med: 5.36 Max: 12.3
Current: 4.29
4.05
12.3
ROC (Joel Greenblatt) % 59.08
PFE's ROC (Joel Greenblatt) % is ranked higher than
87% of the 785 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.40 vs. PFE: 59.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PFE' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 40.74  Med: 57.28 Max: 82.01
Current: 59.08
40.74
82.01
3-Year Revenue Growth Rate 4.70
PFE's 3-Year Revenue Growth Rate is ranked lower than
55% of the 607 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.70 vs. PFE: 4.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PFE' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -2.5  Med: 7.3 Max: 19.2
Current: 4.7
-2.5
19.2
3-Year EBITDA Growth Rate -10.10
PFE's 3-Year EBITDA Growth Rate is ranked lower than
79% of the 583 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.40 vs. PFE: -10.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PFE' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -10.1  Med: 8 Max: 36.8
Current: -10.1
-10.1
36.8
3-Year EPS without NRI Growth Rate -10.80
PFE's 3-Year EPS without NRI Growth Rate is ranked lower than
73% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. PFE: -10.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PFE' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -26.8  Med: 5.6 Max: 90.5
Current: -10.8
-26.8
90.5
GuruFocus has detected 3 Warning Signs with Pfizer Inc $PFE.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PFE's 30-Y Financials

Financials (Next Earnings Date: 2017-08-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

PFE Guru Trades in Q2 2016

Tom Russo 19,900 sh (New)
David Dreman 29,962 sh (+414.81%)
Lee Ainslie 18,426,824 sh (+123.84%)
Jeremy Grantham 12,281,814 sh (+111.72%)
Paul Tudor Jones 21,500 sh (+47.26%)
Pioneer Investments 15,488,287 sh (+45.16%)
Joel Greenblatt 1,938,282 sh (+22.89%)
Ray Dalio 560,639 sh (+21.87%)
Diamond Hill Capital 11,646,559 sh (+3.57%)
Mairs and Power 4,482,288 sh (+1.81%)
Jeff Auxier 85,899 sh (unchged)
Prem Watsa 210,000 sh (unchged)
Robert Bruce 455,332 sh (unchged)
David Carlson 300,000 sh (unchged)
Vanguard Health Care Fund Sold Out
David Tepper Sold Out
Jana Partners Sold Out
Andreas Halvorsen Sold Out
Paul Singer Sold Out
Richard Pzena 2,186,404 sh (-0.03%)
Ken Fisher 31,724,530 sh (-0.07%)
Murray Stahl 68,255 sh (-0.32%)
Ronald Muhlenkamp 37,049 sh (-3.54%)
Mario Gabelli 517,941 sh (-3.55%)
John Buckingham 75,656 sh (-3.60%)
Keeley Asset Management Corp 100,600 sh (-3.73%)
T Rowe Price Equity Income Fund 13,941,800 sh (-5.36%)
Charles Brandes 5,231,096 sh (-5.51%)
Barrow, Hanley, Mewhinney & Strauss 48,981,192 sh (-8.83%)
Manning & Napier Advisors, Inc 651,040 sh (-10.36%)
Dodge & Cox 830,581 sh (-10.65%)
NWQ Managers 2,095,468 sh (-16.80%)
Kahn Brothers 1,156,866 sh (-19.80%)
Jim Simons 1,745,400 sh (-27.77%)
First Eagle Investment 76,061 sh (-46.08%)
RS Investment Management 793,005 sh (-51.79%)
Ruane Cunniff 5,930 sh (-52.34%)
John Paulson 510,400 sh (-62.96%)
John Burbank 420,192 sh (-86.75%)
» More
Q3 2016

PFE Guru Trades in Q3 2016

Jim Simons 8,566,241 sh (+390.79%)
Lee Ainslie 21,380,155 sh (+16.03%)
NWQ Managers 2,360,862 sh (+12.67%)
Ray Dalio 626,339 sh (+11.72%)
Richard Pzena 2,329,636 sh (+6.55%)
Diamond Hill Capital 11,856,263 sh (+1.80%)
Mairs and Power 4,555,073 sh (+1.62%)
Ken Fisher 31,836,368 sh (+0.35%)
David Carlson 300,000 sh (unchged)
David Dreman 29,962 sh (unchged)
Prem Watsa 210,000 sh (unchged)
Eric Mindich 3,050,000 sh (unchged)
Robert Bruce 455,332 sh (unchged)
Ruane Cunniff Sold Out
Tom Russo Sold Out
T Rowe Price Equity Income Fund 13,875,000 sh (-0.48%)
Manning & Napier Advisors, Inc 645,026 sh (-0.92%)
Jeff Auxier 85,015 sh (-1.03%)
John Burbank 409,366 sh (-2.58%)
Ronald Muhlenkamp 36,034 sh (-2.74%)
Mario Gabelli 502,386 sh (-3.00%)
Murray Stahl 65,882 sh (-3.48%)
Barrow, Hanley, Mewhinney & Strauss 47,267,043 sh (-3.50%)
Charles Brandes 5,032,007 sh (-3.81%)
John Buckingham 72,763 sh (-3.82%)
Dodge & Cox 773,142 sh (-6.92%)
Keeley Asset Management Corp 91,630 sh (-8.92%)
Pioneer Investments 13,857,332 sh (-10.53%)
First Eagle Investment 66,061 sh (-13.15%)
Paul Tudor Jones 17,200 sh (-20.00%)
Kahn Brothers 919,757 sh (-20.50%)
Joel Greenblatt 1,158,937 sh (-40.21%)
Jeremy Grantham 6,716,818 sh (-45.31%)
John Paulson 252,000 sh (-50.63%)
» More
Q4 2016

PFE Guru Trades in Q4 2016

Steven Cohen 214,100 sh (New)
David Tepper 4,810,000 sh (New)
Eaton Vance Worldwide Health Sciences Fund 1,462,345 sh (New)
John Paulson 352,200 sh (+39.76%)
Diamond Hill Capital 12,957,027 sh (+9.28%)
Lee Ainslie 22,851,570 sh (+6.88%)
Manning & Napier Advisors, Inc 684,000 sh (+6.04%)
Murray Stahl 69,400 sh (+5.34%)
Charles Brandes 5,271,418 sh (+4.76%)
Mairs and Power 4,725,178 sh (+3.73%)
John Buckingham 74,141 sh (+1.89%)
Ken Fisher 32,204,753 sh (+1.16%)
Jeff Auxier 85,493 sh (+0.56%)
T Rowe Price Equity Income Fund 13,900,000 sh (+0.18%)
David Carlson 300,000 sh (unchged)
First Eagle Investment 66,061 sh (unchged)
Robert Bruce 455,332 sh (unchged)
Prem Watsa 210,000 sh (unchged)
John Burbank Sold Out
Mario Gabelli 490,448 sh (-2.38%)
Keeley Asset Management Corp 89,323 sh (-2.52%)
Dodge & Cox 746,972 sh (-3.38%)
NWQ Managers 2,280,229 sh (-3.42%)
Barrow, Hanley, Mewhinney & Strauss 45,401,940 sh (-3.95%)
Richard Pzena 2,217,509 sh (-4.81%)
Ronald Muhlenkamp 33,984 sh (-5.69%)
Kahn Brothers 860,290 sh (-6.47%)
Jeremy Grantham 5,451,421 sh (-18.84%)
Pioneer Investments 9,476,885 sh (-31.61%)
Joel Greenblatt 759,374 sh (-34.48%)
Paul Tudor Jones 10,900 sh (-36.63%)
David Dreman 18,901 sh (-36.92%)
Ray Dalio 282,200 sh (-54.94%)
Jim Simons 2,847,000 sh (-66.76%)
» More
Q1 2017

PFE Guru Trades in Q1 2017

George Soros 31,200 sh (New)
David Carlson 650,000 sh (+116.67%)
Joel Greenblatt 944,660 sh (+24.40%)
John Paulson 407,500 sh (+15.70%)
Charles Brandes 6,018,005 sh (+14.16%)
Manning & Napier Advisors, Inc 719,433 sh (+5.18%)
Mairs and Power 4,871,107 sh (+3.09%)
Ken Fisher 32,759,530 sh (+1.72%)
Murray Stahl 70,082 sh (+0.98%)
John Buckingham 74,585 sh (+0.60%)
First Eagle Investment 66,061 sh (unchged)
Richard Pzena 2,217,509 sh (unchged)
Prem Watsa 210,000 sh (unchged)
David Dreman 18,901 sh (unchged)
Robert Bruce 455,332 sh (unchged)
Jim Simons Sold Out
Steven Cohen Sold Out
Jeff Auxier 84,868 sh (-0.73%)
Mario Gabelli 485,466 sh (-1.02%)
Ronald Muhlenkamp 33,034 sh (-2.80%)
Diamond Hill Capital 12,358,068 sh (-4.62%)
Barrow, Hanley, Mewhinney & Strauss 42,835,523 sh (-5.65%)
Pioneer Investments 8,844,361 sh (-6.67%)
Dodge & Cox 678,070 sh (-9.22%)
T Rowe Price Equity Income Fund 12,325,000 sh (-11.33%)
Jeremy Grantham 4,786,189 sh (-12.20%)
Lee Ainslie 19,833,477 sh (-13.21%)
Kahn Brothers 667,633 sh (-22.39%)
David Tepper 3,021,000 sh (-37.19%)
Paul Tudor Jones 6,400 sh (-41.28%)
NWQ Managers 1,313,554 sh (-42.39%)
Ray Dalio 62,095 sh (-78.00%)
Eaton Vance Worldwide Health Sciences Fund 1,327,953 sh (-9.19%)
» More
» Details

Insider Trades

Latest Guru Trades with PFE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NYSE:NVS, NYSE:MRK, OTCPK:RHHBY, NYSE:SNY, OTCPK:BAYRY, OTCPK:GLAXF, NYSE:ABBV, NYSE:BMY, NYSE:LLY, NYSE:AZN, NYSE:JNJ, OTCPK:ALPMF, OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:KYKOF, OTCPK:CHPTY, OTCPK:PTKFY, OTCPK:SNPHY » details
Traded in other countries:PFE.Argentina, PFEBC.Belgium, PFIZ34.Brazil, PFE.Chile, PFE.Germany, PFE.Mexico, PFE.Sweden, PFE.Switzerland, 0Q1N.UK,
Headquarter Location:USA
Pfizer Inc is a research-based biopharmaceutical company. The Company's portfolio includes medicines, and vaccines as well as many of the consumer healthcare products.

Pfizer is one of the world's largest pharmaceutical firms, with annual sales over $50 billion. Prescription drugs and vaccines account for the majority of sales. Top sellers include vaccine Prevnar 13 against meningitis and Lyrica for epilepsy and some types of neuropathic pain. Pfizer sells these products globally with international sales representing over 50% of its total sales.

Guru Investment Theses on Pfizer Inc

Gabelli Funds Comments on Pfizer Inc. - Aug 04, 2016

Pfizer Inc. (NYSE:PFE) (3.8%) (PFE – $29.64 – NYSE), headquartered in New York City, is one of the world’s largest research based pharmaceutical companies, with sales of $48.9 billion in 2015. The company’s drugs include the blockbusters Enbrel for autoimmune diseases, Lipitor for high cholesterol, Lyrica for pain, and Viagra for erectile dysfunction. The company’s late-stage pipeline includes drugs being developed to treat cancer, cardiovascular disease, and inflammatory conditions. Pfizer also offers consumer healthcare products, including Advil, Centrum, ChapStick, Emergen-C, and Robitussin. In April 2016, the company terminated its planned acquisition of Allergan plc following unfavorable tax regulations from the U.S. Treasury. Pfizer is now considering whether to split the company into two segments, one for high growth innovative pharmaceuticals and one for lower growth/declining established pharmaceuticals, with a decision expected by the end of 2016.



From the Gabelli Dividend Growth Fund second quarter 2016 commentary.



Check out Mario Gabelli latest stock trades

Top Ranked Articles about Pfizer Inc

Kahn Brothers Sells Hologic, Pfizer, Citigroup The guru's largest 1st-quarter transactions
Irving Kahn, along with brothers Alan and Thomas, founded Kahn Brothers (Trades, Portfolio) in 1978. Kahn Brothers employs a bottom-up stock selection approach and invests in undervalued equity securities that are usually out of favor in the market. During the first quarter the guru sold shares in the following stocks: Read more...
Companies Aiming for the Billion-Dollar Opioid Addiction Market The global opioid market is expected to reach $42.16 billion by 2021
The global opioid market reached $33.924 billion in 2014 and is estimated to have reached $34.89 billion in 2015, data from Persistent Market Research shows. Experts believe the market will reach $42.16 billion by 2021, or a 3.2% compound annual growth rate (CAGR). Read more...
Spark Therapeutics and Pfizer Announce that SPK-9001, an Investigational Hemophilia B Medicine, has been Granted Access to the PRIority MEdicines (PRIME) Program by the European Medicines Agency

PHILADELPHIA and NEW YORK, March 01, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE) and Pfizer Inc. (:PFE) announced today that SPK-9001, the lead investigational candidate in the companies' SPK-FIX program has been granted support through the European Medicines Agency (EMA) PRIority MEdicines (PRIME) program. According to the EMA, PRIME is intended to enhance support for new treatments in development “that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options.”
“We are pleased that investigational SPK-9001 has been granted access to the PRIME program, which potentially will help accelerate the delivery of this potential gene therapy to European patients living with hemophilia B,” said Jeffrey D. Marrazzo, chief executive officer of Spark Therapeutics. “We appreciate the EMA’s dedication to moving treatments forward for patients who are underserved with current options, and we look forward to our continued collaboration on SPK-9001.” SPK-9001 is an experimental treatment for hemophilia B that is currently being investigated in an ongoing Phase 1/2 trial as a potential single-dose therapy. The PRIME program provides enhanced interaction and early dialogue with developers of promising medicines, which is intended to optimize development plans and speed up evaluation so these medicines can reach patients earlier. SPK-9001 received orphan product designation from the U.S. Food and Drug Administration (FDA) in September 2015, and later received breakthrough therapy designation from the FDA in July 2016. About Hemophilia B
Hemophilia, a rare genetic bleeding disorder that causes the blood to take a long time to clot as a result of a deficiency in one of several blood clotting factors, is almost exclusively in males. People with hemophilia are at risk for excessive and recurrent bleeding from modest injuries, which have the potential to be life threatening. People with severe hemophilia often bleed spontaneously into their muscles or joints. The incidence of hemophilia B is one in 25,000 male births. People with hemophilia B have a deficiency in clotting factor IX, a specific protein in the blood. Hemophilia B also is called congenital factor IX deficiency or Christmas disease. Current standard of care requires recurrent intravenous infusions of either plasma-derived or recombinant factor IX to control and prevent bleeding episodes. There exists a significant need for novel therapeutics to treat people living with hemophilia.

About the SPK-FIX Program and SPK-9001
Spark Therapeutics' proprietary technology platform for selecting, designing, manufacturing and formulating gene therapies was applied to developing compounds in the SPK-FIX program. The SPK-FIX program leverages a long history of hemophilia gene therapy research and clinical development conducted by Spark Therapeutics and its founding scientific team over nearly three decades. SPK-9001 is a novel, investigational bio-engineered adeno-associated virus (AAV) capsid expressing a codon-optimized, high-activity human factor IX variant enabling endogenous production of factor IX. SPK-9001 is being developed under a collaboration with Pfizer. Spark Therapeutics and Pfizer entered into a collaboration in December 2014 for the SPK-FIX program, including SPK-9001, under which Spark Therapeutics is responsible for conducting all Phase 1/2 studies for any product candidates, while Pfizer will assume responsibility for pivotal studies, any regulatory activities and potential global commercialization of any products that may result from the collaboration.  About Spark Therapeutics
Spark Therapeutics, a fully integrated company, strives to challenge the inevitability of genetic disease by discovering, developing, and delivering gene therapies that address inherited retinal diseases (IRDs), neurodegenerative diseases, as well as diseases that can be addressed by targeting the liver. Our validated platform successfully has delivered proof-of-concept data with investigational gene therapies in the retina and liver. Our most advanced investigational candidate, voretigene neparvovec, in development for the treatment of biallelic RPE65-mediated IRD, has received orphan designations in the U.S. and European Union, and breakthrough therapy designation in the U.S. The pipeline also includes SPK-7001 in a Phase 1/2 trial for choroideremia, and two hemophilia development programs: SPK-9001 (which also has received both breakthrough therapy and orphan product designations) in a Phase 1/2 trial for hemophilia B being developed in collaboration with Pfizer, and SPK-8011, in a Phase 1/2 trial for hemophilia A to which Spark Therapeutics retains global commercialization rights. To learn more about us and our growing pipeline, visit www.sparktx.com. Spark Cautionary Note on Forward-looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's SPK-FIX program. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that: (i) our lead SPK-FIX product candidate, SPK-9001, may not produce sufficient data in our Phase 1/2 clinical trial to warrant further development; and (ii) our overall collaboration with Pfizer may not be successful. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the "Risk Factors" section, as well as discussions of potential risks, uncertainties and other important factors, in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and other filings we make with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Spark undertakes no duty to update this information unless required by law. Pfizer and Rare Disease
Rare disease includes some of the most serious of all illnesses and impacts millions of patients worldwide,[i] representing an opportunity to apply our knowledge and expertise to help make a significant impact on addressing unmet medical needs. The Pfizer focus on rare disease builds on more than two decades of experience, a dedicated research unit focusing on rare disease, and a global portfolio of multiple medicines within a number of disease areas of focus, including hematology, neuroscience, and inherited metabolic disorders.[ii] Pfizer Rare Disease combines pioneering science and deep understanding of how diseases work with insights from innovative strategic collaborations with academic researchers, patients, and other companies to deliver transformative treatments and solutions. We innovate every day leveraging our global footprint to accelerate the development and delivery of groundbreaking medicines and the hope of cures. Click here to learn more about our Rare Disease portfolio and how we empower patients, engage communities in our clinical development programs, and support programs that heighten disease awareness and meet the needs of patient families. Pfizer Inc: Working together for a healthier world®
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. For more information, please visit us at www.pfizer.com. In addition, to learn more, follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer. Pfizer Disclosure Notice:
The information contained in this release is as of Feb. 28, 2017. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about SPK-9001 and the SPK-FIX program, including their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical study commencement and completion dates as well as the possibility of unfavorable study results, including unfavorable new clinical data and additional analyses of existing clinical data; risks associated with initial data, including the risk that the final results of the Phase 1/2 study for SPK-9001 and/or additional clinical trials may be different from (including less favorable than) the initial data results and may not support further clinical development; whether and when any applications may be filed with regulatory authorities for SPK-9001; whether and when regulatory authorities may approve any such applications, which will depend on the assessment by such regulatory authorities of the benefit-risk profile suggested by the totality of the efficacy and safety information submitted; decisions by regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of SPK-9001; and competitive developments. A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. [i] Rare Disease: Facts and Statistics. http://globalgenes.org/rare-diseases-facts-statistics. Accessed September 7, 2016. [ii] Pfizer Inc. Rare Disease. http://www.pfizer.com/health-and-wellness/health-topics/rare-diseases/areas-of-focus. Accessed December 20, 2016.
Investor Contact: Media Contact:
Ryan Asay Monique da Silva
[email protected] [email protected]
(215) 239-6424 (215) 282-7470

Read more...
Pfizer Reports Top-Line Results for Rheumatoid Arthritis Treatment Study The study compared Xeljanz to Humira
The top-line results from the Oral Strategy trial of Xeljanz were announced Feb. 16 by Pfizer Inc. (NYSE:PFE) through the Business Wire. Read more...
David Tepper Invests Heavily in Pharma in 4th Quarter Guru gains 4 drug manufacturers, adds to Allergan
David Tepper (Trades, Portfolio), founder and president of Appaloosa Management, gained new holdings in pharmaceutical companies in the final quarter of 2016. Read more...
Procter & Gamble, Pfizer Lead Market Gains 3 indexes reach new highs on Wednesday
U.S. market indexes continued to gain on Wednesday with all three leading indexes reaching new highs. Read more...
Pfizer Inc.: Humira's Biosimilar Meets Primary Endpoint Biosimilar for rheumatoid arthritis treatment demonstrated equivalent efficacy
Pfizer Inc. (NYSE:PFE) announced through the Business Wire on Jan. 5 that the results from a phase 3 study assessing the efficiency of PF-06410293, a biosimilar of AbbVie’s (NYSE:ABBV) Humira, in treating patients affected by rheumatoid arthritis met its primary endpoint. Read more...
Gilead’s Patience Is Wearing Investors' Patience Thin Despite sitting on a cash pile, the company has been slow in the acquisitions space
Gilead’s (NASDAQ:GILD) stock price has been on a never-ending slide since the second half of last year. The stock is now trading at less than 7 times earnings after dropping more than a quarter of its valuation in the last twelve months. But a key question that remains after analyzing Gilead is why the company is sitting on its cash pile without doing anything. Read more...
Which Criteria Best Determine the Success of Mergers? An evaluation of 3 recent mergers
Throughout the past three months, several mergers, including the $14 billion merger between Pfizer Inc. (NYSE:PFE) and Medivation Inc. (NASDAQ:MDVN), were announced. In part one of our study, we discussed how the John Paulson Merger Arb Checklist determines the success rate of mergers. This article will further the study by analyzing some of the recent mergers and predicting the success rate based on historical results. Read more...
Pfizer Acquires Medivation Company will pay $14 billion for biopharmaceutical business
Pfizer (NYSE:PFE) reported Monday that it would be acquiring, biopharmaceutical company, Medivation (NASDAQ:MDVN). Pfizer will pay $81.50 per share for a total value of approximately $14 billion. Shares of Medivation opened higher on Monday and gained approximately 20%. Read more...

Ratios

vs
industry
vs
history
PE Ratio 27.01
PFE's PE Ratio is ranked lower than
51% of the 556 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.48 vs. PFE: 27.01 )
Ranked among companies with meaningful PE Ratio only.
PFE' s PE Ratio Range Over the Past 10 Years
Min: 7.68  Med: 16.37 Max: 34.77
Current: 27.01
7.68
34.77
Forward PE Ratio 12.72
PFE's Forward PE Ratio is ranked higher than
95% of the 202 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.39 vs. PFE: 12.72 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 26.78
PFE's PE Ratio without NRI is ranked lower than
52% of the 544 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.85 vs. PFE: 26.78 )
Ranked among companies with meaningful PE Ratio without NRI only.
PFE' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.83  Med: 19.3 Max: 34.43
Current: 26.78
9.83
34.43
Price-to-Owner-Earnings 17.06
PFE's Price-to-Owner-Earnings is ranked higher than
72% of the 293 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.45 vs. PFE: 17.06 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
PFE' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.44  Med: 10.89 Max: 36.49
Current: 17.06
5.44
36.49
PB Ratio 3.36
PFE's PB Ratio is ranked lower than
58% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.03 vs. PFE: 3.36 )
Ranked among companies with meaningful PB Ratio only.
PFE' s PB Ratio Range Over the Past 10 Years
Min: 1.32  Med: 2.44 Max: 3.72
Current: 3.36
1.32
3.72
PS Ratio 3.75
PFE's PS Ratio is ranked lower than
60% of the 721 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. PFE: 3.75 )
Ranked among companies with meaningful PS Ratio only.
PFE' s PS Ratio Range Over the Past 10 Years
Min: 1.72  Med: 3.6 Max: 4.74
Current: 3.75
1.72
4.74
Price-to-Free-Cash-Flow 14.48
PFE's Price-to-Free-Cash-Flow is ranked higher than
72% of the 226 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.83 vs. PFE: 14.48 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PFE' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.02  Med: 12.98 Max: 18.91
Current: 14.48
5.02
18.91
Price-to-Operating-Cash-Flow 12.57
PFE's Price-to-Operating-Cash-Flow is ranked higher than
63% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.62 vs. PFE: 12.57 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PFE' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.55  Med: 11.68 Max: 15.89
Current: 12.57
4.55
15.89
EV-to-EBIT 22.32
PFE's EV-to-EBIT is ranked higher than
91% of the 776 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.99 vs. PFE: 22.32 )
Ranked among companies with meaningful EV-to-EBIT only.
PFE' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.7  Med: 14.5 Max: 28.8
Current: 22.32
6.7
28.8
EV-to-EBITDA 14.01
PFE's EV-to-EBITDA is ranked higher than
95% of the 797 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.26 vs. PFE: 14.01 )
Ranked among companies with meaningful EV-to-EBITDA only.
PFE' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.9  Med: 9.3 Max: 17.3
Current: 14.01
4.9
17.3
Shiller PE Ratio 20.38
PFE's Shiller PE Ratio is ranked higher than
81% of the 161 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 43.67 vs. PFE: 20.38 )
Ranked among companies with meaningful Shiller PE Ratio only.
PFE' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.05  Med: 16.79 Max: 25.1
Current: 20.38
9.05
25.1
Current Ratio 1.44
PFE's Current Ratio is ranked lower than
81% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.55 vs. PFE: 1.44 )
Ranked among companies with meaningful Current Ratio only.
PFE' s Current Ratio Range Over the Past 10 Years
Min: 0.98  Med: 1.53 Max: 3.18
Current: 1.44
0.98
3.18
Quick Ratio 1.14
PFE's Quick Ratio is ranked lower than
77% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.85 vs. PFE: 1.14 )
Ranked among companies with meaningful Quick Ratio only.
PFE' s Quick Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.23 Max: 2.86
Current: 1.14
0.74
2.86
Days Inventory 225.46
PFE's Days Inventory is ranked lower than
85% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.29 vs. PFE: 225.46 )
Ranked among companies with meaningful Days Inventory only.
PFE' s Days Inventory Range Over the Past 10 Years
Min: 185.33  Med: 229.24 Max: 344.63
Current: 225.46
185.33
344.63
Days Sales Outstanding 61.70
PFE's Days Sales Outstanding is ranked higher than
67% of the 636 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.05 vs. PFE: 61.70 )
Ranked among companies with meaningful Days Sales Outstanding only.
PFE' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.83  Med: 69.5 Max: 106.89
Current: 61.7
56.83
106.89
Days Payable 103.66
PFE's Days Payable is ranked higher than
80% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.53 vs. PFE: 103.66 )
Ranked among companies with meaningful Days Payable only.
PFE' s Days Payable Range Over the Past 10 Years
Min: 73.72  Med: 115.45 Max: 179.46
Current: 103.66
73.72
179.46

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.85
PFE's Dividend Yield % is ranked higher than
86% of the 673 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.58 vs. PFE: 3.85 )
Ranked among companies with meaningful Dividend Yield % only.
PFE' s Dividend Yield % Range Over the Past 10 Years
Min: 2.9  Med: 3.68 Max: 10.4
Current: 3.85
2.9
10.4
Dividend Payout Ratio 1.03
PFE's Dividend Payout Ratio is ranked lower than
74% of the 410 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.35 vs. PFE: 1.03 )
Ranked among companies with meaningful Dividend Payout Ratio only.
PFE' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.58  Med: 0.77 Max: 1.08
Current: 1.03
0.58
1.08
3-Year Dividend Growth Rate 7.70
PFE's 3-Year Dividend Growth Rate is ranked higher than
51% of the 285 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. PFE: 7.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
PFE' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -14.7  Med: 12.6 Max: 22.6
Current: 7.7
-14.7
22.6
Forward Dividend Yield % 3.94
PFE's Forward Dividend Yield % is ranked higher than
87% of the 658 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.59 vs. PFE: 3.94 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 5.76
PFE's 5-Year Yield-on-Cost % is ranked higher than
89% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.09 vs. PFE: 5.76 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
PFE' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 4.34  Med: 5.51 Max: 15.57
Current: 5.76
4.34
15.57
3-Year Average Share Buyback Ratio 1.70
PFE's 3-Year Average Share Buyback Ratio is ranked higher than
96% of the 442 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.30 vs. PFE: 1.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PFE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17.6  Med: 0.1 Max: 7.2
Current: 1.7
-17.6
7.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.04
PFE's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
83% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.56 vs. PFE: 1.04 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
PFE' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.53  Med: 1.45 Max: 9.98
Current: 1.04
0.53
9.98
Price-to-Median-PS-Value 1.04
PFE's Price-to-Median-PS-Value is ranked higher than
52% of the 645 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. PFE: 1.04 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PFE' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.43  Med: 1.06 Max: 3.31
Current: 1.04
0.43
3.31
Earnings Yield (Greenblatt) % 4.47
PFE's Earnings Yield (Greenblatt) % is ranked higher than
93% of the 1046 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.36 vs. PFE: 4.47 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PFE' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.5  Med: 6.9 Max: 14.9
Current: 4.47
3.5
14.9
Forward Rate of Return (Yacktman) % 2.87
PFE's Forward Rate of Return (Yacktman) % is ranked lower than
63% of the 369 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.72 vs. PFE: 2.87 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
PFE' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 2.5  Med: 12.6 Max: 23.3
Current: 2.87
2.5
23.3

More Statistics

Revenue (TTM) (Mil) $52,599
EPS (TTM) $ 1.19
Beta1.04
Short Percentage of Float0.80%
52-Week Range $29.83 - 37.39
Shares Outstanding (Mil)5,967.84

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 52,870 53,942 53,367
EPS ($) 2.54 2.75 2.80
EPS without NRI ($) 2.54 2.75 2.80
EPS Growth Rate
(Future 3Y To 5Y Estimate)
5.01%
Dividends per Share ($) 1.28 1.36 1.45
» More Articles for PFE

Headlines

Articles On GuruFocus.com
Investors: Option reports for Citigroup, The Gap, Nike, NVIDIA and Pfizer Inc. include trade ideas t May 22 2017 
Nasdaq Reports Another New High May 16 2017 
Sangamo Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene Th May 16 2017 
Covered Call reports for Apple, Coty Inc., NVIDIA, Pfizer Inc. and Yelp include trade ideas that off May 11 2017 
Sangamo Therapeutics And Pfizer Announce Collaboration For Hemophilia A Gene Therapy May 10 2017 
FDA Grants BAVENCIO® (avelumab) Approval for a Common Type of Advanced Bladder Cancer May 09 2017 
Investors: Covered Call reports for Exelixis, Facebook, Priceline, Pfizer Inc. and AT&T include trad May 02 2017 
Aquinnah Pharmaceuticals Receives $10 Million Investment from Pfizer and AbbVie to Research Breakthr Apr 25 2017 
FDA Rejects Eli Lilly, Incyte's Commercialization Application Apr 18 2017 
Large-Cap Stocks Mostly Lower With Health Care Vote Uncertainty Mar 24 2017 

More From Other Websites
The 3 Best Dividend Stocks in Arthritis Medication May 22 2017
3 Ways Johnson & Johnson's Pharmaceutical Business Plans to Beat the Market May 21 2017
3 Stocks to Supplement Your Social Security Income May 20 2017
[$$] Iterum Therapeutics Lines Up Funding Ahead of Trials May 19 2017
ETFs with exposure to Pfizer Inc. : May 19, 2017 May 19 2017
Billionaire George Soros Is Warming Up to This Big Pharma Stock. Should You? May 19 2017
CHMP backs Novartis's Zykadia for first-line use in lung cancer May 19 2017
Conference Spotlights Drug Giant Donnybrooks In Cancer Treatments May 18 2017
Pfizer Inc. :PFE-US: Earnings Analysis: Q1, 2017 By the Numbers : May 18, 2017 May 18 2017
The Zacks Analyst Blog Highlights: Pfizer, Home Depot, ConocoPhillips, Prudential Financial and... May 18 2017
The Lancet Publishes Phase 2 Results from Shire's Investigational Anti-MAdCAM Antibody Showing... May 18 2017
A Doomed Trump Presidency Would Be a Terrifying Development for Pharmaceutical Stocks May 18 2017
[$$] Some Biotech Companies Making the Cut in Narrower IPO Market May 18 2017
Pfizer Oncology to Present Data Across 13 Different Types of Cancer at ASCO 2017 Annual Meeting May 17 2017
Astellas Announces Oncology Portfolio Updates May 17 2017
Pfizer drug from Medivation deal shows promise in breast cancer -study May 17 2017
Stock Market Today & Home Depot, Pfizer and ConocoPhillips Research Reports May 17 2017
Eli Lilly: Worries Ahead In Patent Fight May 17 2017
Pfizer Invites Public to View and Listen to Webcast of June 9 Conference Call with Analysts to... May 17 2017
3 Dividend Stocks Perfect for Senior Citizens May 17 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat